BioSpace News Archive

Business Highlights - Q4 revenue of $1.791 billion, up 17.5%; organic revenue growth of 14.9% - Q4 Adjusted EBITDA $319.9 million, expansion of 60 basis points - Q4 EPS of $0.06; adjusted EPS of $0.29, growth of 57.2% - Q4 operating cash flow $306 million; free cash flow $286 million, growth of 282% [03-February-2021]

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2020.

Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has commenced an underwritten public offering of $200.0 million of its common stock.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the company’s chief financial officer, Charles N. York II,

Veracyte, Inc. announced that it has commenced an underwritten public offering of $400.0 million in shares of its common stock.

PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Wednesday, Feb. 24, 2021, at 9 a.m. (U.S. Eastern Time) to discuss its fourth quarter and full-year 2020 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD’s website at https://investors.ppd.com .

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 743,495, common shares of the Company (the “Common Shares”), at a price

Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics Expands TAM with presence in 7 of the 10 most common cancers Expected to accelerate revenue growth

Veracyte, Inc . (Nasdaq: VCYT) today announced preliminary results for the fourth quarter and full year ended December 31, 2020. The company expects to report total revenue of between $34.0 million and $35.0 million and product and testing volume of between 13,000 and 13,200 tests for the fourth quarter ended December 31, 2020

Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that it has entered into a definitive agreement with a consortia comprising Aarhus University, Skive Hospital and Statens Serum Institut of Denmark, and obtained the exclusive worldwide license to inventions resulting from an investigator-initiated Phase 2 trial of Osel’s investigational LBP, LACTIN-V,